A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Early Breast Cancer
Interventions: DRUG: Ribociclib|OTHER: Endocrine Therapy
Sponsor: Novartis Pharmaceuticals
Collaborators: Translational Research in Oncology